RNAi Therapeutics 2008 Market Report

Table of Contents

Chapter I. Executive Summary

Chapter II. Opportunities and Challenges In the Space

Chapter III. RNAi Therapeutics Market Analysis: Results of Market Survey performed by Select Biosciences to Analyze the Market Landscape

• Geographic Distribution of the Respondent Pool
• Affiliation of the Respondent Pool
• Challenges Impacting RNAi Therapeutics by Therapeutic/ Disease Area
• Top-Most Challenge by Therapeutic/ Disease Area
• Timeline of Impact by Therapeutic Area
• Delivery Approach by Therapeutic Area
• Drug Target Classes amenable to RNAi Therapeutics
• Druggability Factors
• Factors that determine whether a given drug target will be druggable via RNAi-based therapeutics
• Key Challenges for RNAi-based therapeutics
• Opportunities in the RNAi-based Therapeutics marketplace -- [ie., what products/ services would be of value to the industry]

Chapter IV. RNAi Therapeutics in Development

• Cancer
• Cardiac Disease
• Immunologic Disease
• Infectious Disease
• Inflammation
• Lifestyle
• Metabolic Disease
• Neurologic Disease
• Opthalmic Disease
• Renal Disease
• Respiratory Disease

Appendix I. Research Methodology

Appendix II. Technology Trends in the RNA Interference (RNAi) Space

• Scope
• End-user Segmentation
• Technologies for Inducing RNAi
• Methods for Detecting Gene Silencing
• Libraries of siRNAs/ shRNAs to Knock-down Genes en masse
• Publicly-Available Large-scale Mammalian RNAi Libraries
• The RNAi Consortium (TRC): A Cooperative Effort to
• Generate Large Libraries for Gene Knockdown
• Comparison of Strategies for Target Validation, Especially in the Pharmaceutical Industry
• Market Shifts in the RNAi Space: Where is the Field Heading?
• MicroRNA-based RNAi Interference: The Leading-Edge of the RNAi Space
• Biological Function of microRNAs
• Role of MicroRNAs in Cancer
• MicroRNAs in Human Cancer: The Different Molecular Entities Identified and the Conflicting Experimental Evidence Thus Far
• SWOT Analysis of the Various Technologies in the RNAi Space, and Vendors Commercializing These Technologies

Appendix III. Intellectual Property [IP] in the RNAi Therapeutics Space

• Timeline
• Key Founding IP
• RNAi Patent Landscape and key claims in major patents
• RNAi Therapeutics IP Landscape-2D Maps of the Space, annotated with patent filings for some of the key companies in the RNAi therapeutics space

Appendix IV. Relevant Company Profiles

• Alnylam Pharmaceuticals, Inc.
• Benitec Ltd.
• Calando Pharma
• Intradigm
• Nastech Pharmaceutical Company, Inc.
• Nucleonics, Inc.
• Opko Corporation
• Quark Biotech
• RXi Pharmaceuticals
• Santaris Pharma A/ S
• Silence Therapeutics AG